KCM Capital’s Bristol-Myers Squibb BMY Stock Holding History

KCM Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.79M	Hold	65,800	–	–	0.61%	28
2026 Q1	$3.99M	Buy	+65,800	New	+$3.84M	0.64%	27

Other funds holding BMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

KCM Capital's BMY Position: Q2 2026 in Review

KCM Capital held its Bristol-Myers Squibb (BMY) position steady in Q2 2026 at 65,800 shares worth $3.79M. The position accounts for 0.61% of the portfolio, ranked #28.

KCM Capital first reported a position in BMY in Q1 2026 and has held it in 2 quarters since. The position peaked at $3.99M in Q1 2026. 2,514 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

KCM Capital held 65,800 shares of Bristol-Myers Squibb worth $3.79M as of Q2 2026.
KCM Capital left its Bristol-Myers Squibb share count unchanged in Q2 2026.
Bristol-Myers Squibb made up 0.61% of KCM Capital's portfolio in Q2 2026, its #28 holding.
KCM Capital first reported a position in Bristol-Myers Squibb in Q1 2026 and has held it in 2 quarters since.
KCM Capital's Bristol-Myers Squibb position peaked at $3.99M in Q1 2026.
2,514 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on KCM Capital's 13F filing for Q2 2026, filed 12 Aug 2026.